PACIFIC EDGE ORD FOR.EXEMPT NZX (PEB) Short Interest

PACIFIC EDGE ORD FOR.EXEMPT NZX (ASX:PEB) had 0.10% of shares reported as short positions as of 16 May 2026, representing 1,063,942 shares. PACIFIC EDGE ORD FOR.EXEMPT NZX operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).

Short interest
0.10%
Reported positions
1,063,942
Industry
Pharmaceuticals, Biotechnology & Life Sciences
As of
16 May 2026

Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.

Pacific Edge logo

PEB

Pacific Edge

Pharmaceuticals, Biotechnology & Life Sciences

Pacific Edge is a global cancer diagnostics company focused on developing and commercializing bladder cancer diagnostic and prognostic tests. Their key product, Cxbladder, is a suite of non-invasive genomic urine tests used for risk stratification, rule-out, and surveillance of urothelial bladder cancer. The company operates directly in New Zealand, Australia, Singapore, and the United States, and...

cancer diagnostics
genomics
bladder cancer
Cxbladder

Shorted

short percentage0.10%
reported shorts1.1M
shares on issue1.023B